Literature DB >> 11594929

Acute disseminated encephalomyelitis associated with hepatitis C virus infection.

S Sacconi1, L Salviati, E Merelli.   

Abstract

BACKGROUND: Acute disseminated encephalomyelitis (ADEM) is an autoimmune demyelinating disease of the central nervous system that is frequently preceded by an acute viral infection. This is the first reported case of ADEM associated with hepatitis C virus (HCV) infection. CASE DESCRIPTION: A 46-year-old woman underwent a surgical procedure and received multiple blood transfusions, at which time serologic testing for HCV was negative. Fifty days later, she suddenly developed seizures, alteration of consciousness, right hemiparesis, hemianopsia, and urinary retention. Magnetic resonance imaging revealed symmetric multifocal changes on T2-weighted images in the cerebral gray and white matter and in the cerebellar white matter with some lesion enhancement after gadolinium administration. Blood testing showed a recent HCV infection with high titer of IgM early antigens and a strongly positive reaction for HCV RNA. All other microbiological and virological test results were negative both in serum and in cerebrospinal fluid. Treatment with high-dose dexamethasone was followed by a dramatic improvement of the clinical and magnetic resonance picture. Within a few months the patient recovered completely and there were no relapses during 2 years of follow-up.
CONCLUSIONS: Infection with HCV is associated with several autoimmune neurological manifestations. It is recommended the patients with ADEM be screened for HCV.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11594929     DOI: 10.1001/archneur.58.10.1679

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  16 in total

1.  Multifocal central and peripheral demyelination associated with hepatitis C virus infection.

Authors:  T A Mestre; J Correia de Sá; J Pimentel
Journal:  J Neurol       Date:  2007-12-17       Impact factor: 4.849

Review 2.  Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview.

Authors:  Luigi Elio Adinolfi; Riccardo Nevola; Giacomo Lus; Luciano Restivo; Barbara Guerrera; Ciro Romano; Rosa Zampino; Luca Rinaldi; Ausilia Sellitto; Mauro Giordano; Aldo Marrone
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

Review 3.  Neurological complications of hepatitis C infection.

Authors:  Micheline McCarthy; Melissa R Ortega
Journal:  Curr Neurol Neurosci Rep       Date:  2012-12       Impact factor: 5.081

Review 4.  [Acute disseminated encephalomyelitis. Pathogenesis, diagnosis, treatment, and prognosis].

Authors:  O Stüve; S Nessler; H P Hartung; B Hemmer; H Wiendl; B C Kieseier
Journal:  Nervenarzt       Date:  2005-06       Impact factor: 1.214

Review 5.  Hepatitis C virus and neurological damage.

Authors:  Shilu Mathew; Muhammed Faheem; Sara M Ibrahim; Waqas Iqbal; Bisma Rauff; Kaneez Fatima; Ishtiaq Qadri
Journal:  World J Hepatol       Date:  2016-04-28

6.  Clinicopathologic correlates of hepatitis C virus in brain: a pilot study.

Authors:  Jacinta Murray; Sarah L Fishman; Elizabeth Ryan; Francis J Eng; José L Walewski; Andrea D Branch; Susan Morgello
Journal:  J Neurovirol       Date:  2008-01       Impact factor: 2.643

Review 7.  HCV-related nervous system disorders.

Authors:  Salvatore Monaco; Sergio Ferrari; Alberto Gajofatto; Gianluigi Zanusso; Sara Mariotto
Journal:  Clin Dev Immunol       Date:  2012-07-30

8.  A case of acute disseminated encephalomyelitis associated with hepatitis C virus infection.

Authors:  Jae Eun Sim; Jun-Bum Lee; Yu Na Cho; Sang Hyun Suh; Ja Kyung Kim; Kyung-Yul Lee
Journal:  Yonsei Med J       Date:  2012-07-01       Impact factor: 2.759

Review 9.  Postinfectious encephalomyelitis.

Authors:  Dean M Wingerchuk
Journal:  Curr Neurol Neurosci Rep       Date:  2003-05       Impact factor: 6.030

Review 10.  HCV-related central and peripheral nervous system demyelinating disorders.

Authors:  Sara Mariotto; Sergio Ferrari; Salvatore Monaco
Journal:  Inflamm Allergy Drug Targets       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.